Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Journal of Health Economics and Outcomes Research
|
June 28, 2021
Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, et al.
Melanoma Research
|
April 18, 2015
Comparative healthcare costs in patients with metastatic melanoma in the USA
Chun-Lan Chang, Vernon F Schabert, Julie Munakata, et al.
Patient Preference and Adherence
|
December 2, 2020
Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
Wing Chow, Prina Donga, Aurélie Côté-Sergent, et al.
Current Medical Research and Opinion
|
May 28, 2020
An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
Wing Chow, Prina Donga, Aurélie Côté-Sergent, et al.
Current Medical Research and Opinion
|
November 23, 2021
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
July 31, 2023
Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
Prina Donga, Bruno Emond, Carmine Rossi, et al.
Journal of Comparative Effectiveness Research
|
November 29, 2022
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors
Prina Donga, Bruno Emond, Aditi Shah, et al.
Infectious Diseases and Therapy
|
August 2, 2022
Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy
Grace A McComsey, Bruno Emond, Aditi Shah, et al.
Journal of the International AIDS Society
|
June 12, 2023
Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
Peter F Rebeiro, Bruno Emond, Carmine Rossi, et al.
Rheumatology International
|
August 29, 2015
Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany
Ramon Lyu, Marinella Govoni, Qian Ding, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Journal of Health Economics and Outcomes Research
|
June 28, 2021
Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, et al.
Melanoma Research
|
April 18, 2015
Comparative healthcare costs in patients with metastatic melanoma in the USA
Chun-Lan Chang, Vernon F Schabert, Julie Munakata, et al.
Patient Preference and Adherence
|
December 2, 2020
Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
Wing Chow, Prina Donga, Aurélie Côté-Sergent, et al.
Current Medical Research and Opinion
|
May 28, 2020
An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
Wing Chow, Prina Donga, Aurélie Côté-Sergent, et al.
Current Medical Research and Opinion
|
November 23, 2021
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
July 31, 2023
Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
Prina Donga, Bruno Emond, Carmine Rossi, et al.
Journal of Comparative Effectiveness Research
|
November 29, 2022
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors
Prina Donga, Bruno Emond, Aditi Shah, et al.
Infectious Diseases and Therapy
|
August 2, 2022
Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy
Grace A McComsey, Bruno Emond, Aditi Shah, et al.
Journal of the International AIDS Society
|
June 12, 2023
Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
Peter F Rebeiro, Bruno Emond, Carmine Rossi, et al.
Rheumatology International
|
August 29, 2015
Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany
Ramon Lyu, Marinella Govoni, Qian Ding, et al.
Page
of 2